California's $212 Million Investment in Gene Therapy and Bad News from bluebird
Two bluebird Patients with Cancer, Trials Suspended, CIRM Says its Trials Are Okay
Nick Leschly, bluebird bio CEO. Blue Matter photo
California’s stem cell agency has invested $212 million in research involving gene therapy, a field that took a beating this week both scientifically and financially.
The bad news came Tuesday when bluebird bio, a Massachusetts firm, suspended two of its clinical trials for sickle cell disease because two …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.